INDICATIONS AND USAGE（适应症）

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

DOSAGE（服用剂量）

Select patients for the treatment of metastatic NSCLC with ALUNBRIG based on the presence of ALK positivity in tumor specimens.

Recommended Dosage

The recommended dosage for ALUNBRIG is:

90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.

Administer ALUNBRIG until disease progression or unacceptable toxicity.

If ALUNBRIG is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose.

ALUNBRIG may be taken with or without food. Instruct patients to swallow tablets whole. Do not crush or chew tablets.

If a dose of ALUNBRIG is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of ALUNBRIG at the scheduled time.

ADVERSE REACTIONS（不良反应）

Interstitial Lung Disease (ILD)/Pneumonitis

Hypertension

Bradycardia

Visual Disturbance

Creatine Phosphokinase (CPK) Elevation

Pancreatic Enzymes Elevation

Hyperglycemia

Photosensitivity

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/0fe9ff20-d402-41f3-bc1e-7002ea7007db/spl-doc?hl=Alunbrig

Biganibinformation